ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

MARITZA MELENDEZ NIEVES MD

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

14,100Medicare Part D Prescriptions Filled, Including Refills

Rank: 40 out of 384

$818K Total Retail Price of All Prescriptions

Rank: 13 out of 384

427 Patients Receiving at Least One Drug in Part D
74%Patients 65 Years and Older
3% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Puerto Rico
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

2% of this provider’s 11,052 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $45 among peers.

Prescriptions per Patient

33 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Puerto Rico
ATORVASTATIN CALCIUM 1,087 870 1 22
LOSARTAN POTASSIUM 1,013 799 2 5
GABAPENTIN 604 455 3 4
SIMVASTATIN 538 436 4 1
ISOSORBIDE MONONITRATE ER 526 465 5 28
ALENDRONATE SODIUM 450 361 6 20
LOSARTAN-HYDROCHLOROTHIAZIDE 436 330 7 10
OMEPRAZOLE 368 278 8 8
DOXAZOSIN MESYLATE 365 303 9 29
TAMSULOSIN HCL 351 323 10 25
GLIPIZIDE XL 344 287 11 115
FUROSEMIDE 341 308 12 17
GLIPIZIDE ER 290 233 13 105
TRAMADOL HCL-ACETAMINOPHEN 273 200 14 13
PLAVIX 237 218 15 32
METOPROLOL SUCCINATE 236 203 16 21
SYNTHROID 227 189 17 9
LEVOTHYROXINE SODIUM 218 193 18 11
MEGESTROL ACETATE 196 170 R 19 162
CLOPIDOGREL 191 183 20 30
NAMENDA 184 173 21 67
LYRICA 170 90 22 92
SINGULAIR 166 117 23 63
DILTIAZEM HCL 132 121 24 157
ASPIRIN EC 128 83 25 31
CARVEDILOL 125 96 26 23
ISOSORBIDE DINITRATE 120 108 27 118
ZOLPIDEM TARTRATE 119 54 28 19
RAMIPRIL 114 107 29 51
DIOVAN HCT 112 105 30 66
NABUMETONE 109 57 31 34
ONGLYZA 101 81 32 203
CENTRUM CARDIO 95 78 10 33 375
AVODART 92 91 34 179
LANTUS 87 72 35 42
KOMBIGLYZE XR 84 70 36 283
EXELON 81 75 37 136
MECLIZINE HCL 78 62 38 73
PREDNISONE 78 54 38 56
FAMOTIDINE 73 63 40 35
PANTOPRAZOLE SODIUM 72 52 41 39
CLOTRIMAZOLE-BETAMETHASONE 70 49 42 58
JANUMET 69 52 43 116
RANITIDINE HCL 68 41 44 7
BUMETANIDE 67 37 45 195
NAPROXEN SODIUM 63 28 46 164
ACTOS 62 54 47 169
CYMBALTA 62 27 47 71
ACTOPLUS MET 58 51 49 443
ZETIA 58 34 49 69
PAROXETINE HCL 56 46 51 37
LACTULOSE 55 36 52 270
MONTELUKAST SODIUM 54 23 53 146
CARAFATE 53 40 54 178
DIOVAN 53 49 54 54
AVELOX 50 38 56 249
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.